Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STABLE-SR IV: RFCA vs AADs in AF with HFpEF
NCT06125925Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2023
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Composite endpoint of worsening heart failure requiring unplanned hospitalizations or urgent visits, and cardiovascular death at 36 months. Started Nov 2023; status: recruiting.
Beyond the preview
Go deeper on NCT06125925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06125925.